GBP2 and chronic myelogenous leukemia, BCR-ABL1 positive: Although paclitaxel is currently not an established treatment option for treating CML, we found that paclitaxel induced apoptotic death of CML cells, and this activity was dependent on the presence of GBP2, as GBP2 KO cells were distinctively resistant to paclitaxel (Fig. 5f, g).